Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a botulinum toxin presented as a sterile injectable for intramuscular use. It provides temporary muscle relaxation for neurological and movement‑disorder conditions in adult patients. The product is approved for use in the European Union and is administered by qualified healthcare professionals.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering through reliable, comprehensive sourcing, regulatory support and cold‑chain logistics where required.

Letybo, a botulinum toxin type A preparation, is used to manage several neuromuscular and hypersecretory disorders.

- Cervical dystonia: reduces abnormal neck muscle contractions and associated pain. - Blepharospasm: relieves involuntary eyelid closure and improves visual function. - Chronic migraine: decreases the frequency of migraine days in eligible adults. - Upper‑limb spasticity: improves range of motion and functional use of the arm. - Severe axillary hyperhidrosis: diminishes excessive sweating in the underarm area.

Adverse reactions are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects: - Injection site pain or tenderness. - Localized bruising or erythema. - Headache or flu‑like symptoms. - Transient muscle weakness near the injection area. - Mild nausea or fatigue. - Temporary drooping of eyelid (ptosis) when injected near the eye.

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing. - Respiratory compromise due to spread of paralysis. - Generalized muscle weakness resembling botulism. - Allergic reactions including anaphylaxis. - Vision changes such as blurred vision. - Urinary retention or difficulty voiding.

Before initiating therapy with Letybo, clinicians should evaluate patient‑specific risk factors and follow safe handling practices. - Neuromuscular disease assessment: avoid or use with caution in patients with myasthenia gravis, Lambert‑Eaton syndrome or ALS. - Infection control: do not inject into sites with active infection or inflammation. - Anticoagulant use: monitor for increased bruising or hematoma formation. - Systemic spread: observe for signs of distant muscle weakness or respiratory difficulty. - Hypersensitivity: contraindicated in individuals with known allergy to botulinum toxin preparations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics: can potentiate neuromuscular blockade. - Quinine or quinidine: may increase risk of muscle weakness. - Botulinum antitoxin: neutralizes therapeutic effect.

Moderate Interactions (Monitor Closely): - Muscle relaxants (e.g., baclofen, tizanidine): may enhance local paralysis. - General anesthetics (e.g., succinylcholine, non‑depolarizing agents): monitor intra‑operative muscle response. - Anticholinergic agents: may modify glandular effects. - Beta‑blockers: observe for altered cardiovascular response during treatment.